Retraction Note: Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS

X. Wang, F. Yu, W.-Q. Zheng

Department of Pharmacy, Weihai Central Hospital, Weihai, China

---

• Geriatrics

The article “Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS” by X. Wang, F. Yu, W.-Q. Zheng, published in Eur Rev Med Pharmacol Sci 2019; 23 (3 Suppl): 294-303–DOI: 10.26355/eurrev_201908_18660–PMID: 31389594 has been retracted by the Editor in Chief.

The authors contacted the journal in June 2024, requesting to withdraw the article. Following this request, the journal discovered that the article was commented on PubPeer (link: https://pubpeer.com/publications/DE4E22B2B9E506EDC2E650C58152E0). The journal started an investigation and asked the authors to provide answers to the concerns raised as well as to send the raw data.

Following the journal’s requests, the authors neither responded nor provided the raw data.

The journal’s investigation revealed duplications between panels Blank, HG+1 umol/l, and HG+10 umol/l of Figure 4A.

Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article.

This article has been retracted. The Publisher apologizes for any inconvenience this may cause.

Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS

Free PDF Download